“𝐈𝐧 𝐭𝐨𝐝𝐚𝐲’𝐬 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐢𝐬 𝐚 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐬𝐭𝐞𝐩 𝐢𝐧 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲𝐢𝐧𝐠 𝐭𝐡𝐞 𝐜𝐨𝐫𝐫𝐞𝐜𝐭 𝐭𝐚𝐫𝐠𝐞𝐭 𝐜𝐨𝐧𝐬𝐮𝐦𝐞𝐫𝐬 𝐚𝐧𝐝 𝐩𝐫𝐨𝐯𝐢𝐝𝐢𝐧𝐠 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐬𝐞𝐝 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞𝐢𝐫 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐧𝐞𝐞𝐝𝐬. 𝐖𝐡𝐢𝐥𝐞 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞𝐬𝐞 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬, 𝐞𝐯𝐞𝐫𝐲 𝐟𝐚𝐜𝐞𝐭 𝐚𝐧𝐝 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐩𝐫𝐨𝐛𝐥𝐞𝐦 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐛𝐲 𝐭𝐡𝐞 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫 𝐬𝐞𝐜𝐭𝐨𝐫 𝐢𝐬 𝐭𝐡𝐨𝐫𝐨𝐮𝐠𝐡𝐥𝐲 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐞𝐝. 𝐈𝐭 𝐚𝐥𝐬𝐨 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐬 𝐧𝐮𝐦𝐞𝐫𝐨𝐮𝐬 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐫𝐞𝐟𝐨𝐫𝐦𝐬, 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭, 𝐜𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐛𝐞𝐡𝐚𝐯𝐢𝐨𝐮𝐫, 𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐚𝐧𝐝 𝐟𝐮𝐭𝐮𝐫𝐞 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬, 𝐚𝐧𝐝 𝐫𝐚𝐩𝐢𝐝𝐥𝐲 𝐜𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐭𝐞𝐜𝐡𝐧𝐢𝐜𝐚𝐥 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬. 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐢𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐩𝐥𝐚𝐧𝐬 𝐚𝐧𝐝 𝐩𝐨𝐥𝐢𝐜𝐢𝐞𝐬.”
P2X7 Receptor Antagonist Market Insights
As a pain medication, a P2X7 Receptor Antagonist (or RA) is a drug that blocks the activity of this ligand in the brain. The P2X7 receptor is a key molecule in the initiation of inflammatory processes in the body. However, the mechanisms of P2X7 antagonists remain poorly understood, which hampers the development of effective therapies for patients suffering from chronic pain.
In the disease model of SODG93A mice, a P2X7R antagonist has been shown to slow down the progression of ALS. In a study in which BBG was administered intraperitoneally at 45.5 mg/kg every 48 hours, the drug was found to improve motor performance more in males than in females, but had no effect on survival. As with other drugs, P2X7 Receptor Antagonists should only be used after thorough research.
The mechanism of action of a P2X7 Receptor Antagonist is unknown, but the research suggests that it prevents the retraction of the drug-binding pocket and the formation of turret-like architecture during channel opening. These findings will help guide the development of P2X7-specific drugs. In the meantime, these new compounds can help patients manage pain by enhancing their immune systems.
To Get more information Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2595
Increasing use of P2X7 receptor antagonists in treatment of various diseases is driving the global P2X7 receptor antagonist market growth
Various research studies reported activation of P2X7 channels owing to release of pro-inflammatory cytokines IL-1b and IL-18. As adenosine triphosphate (ATP) has lowest affinity for P2X7 among all other purinergic ion channels (P2X4, P2X3, and others), extracellular ATP rarely activates P2X7 channel. P2X7 receptor antagonists have significant therapeutic potential, as P2X7 receptors have been found to be associated with regulation of inflammation, and all immune cell types (lymphocytes, macrophages, monocytes, and others) express P2X7R. Moreover, P2X7 ion channel has been directly linked to major depression and animal studies have shown that antagonism of P2X7 with centrally penetrant antagonists resulted in antidepressant-like behavior in animal models. Thus, inflammation, pain indications, mood disorders, and depression are the potential areas among others where, P2X7 is involved, and its antagonism can modify disease outcomes, or can be a disease-modifying therapy. As such, P2X7 is an ideal drug target as antagonism of P2X7 channel would not cause any serious side effects, as antagonism will only start when the channel is activated by high ATP concentrations, believed to happen during pathology of neuroinflammatory disorders of the Central Nervous System (CNS) such as stroke, epilepsy, multiple sclerosis, chronic neurodegenerative, and neuropsychiatric diseases. These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.
The global P2X7 receptor antagonist market size was US$ 96.6 million in 2024, and is expected to witness a robust CAGR of 18.3% over the forecast period (2024–2026).
Get Free PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/2595
Robust early stage pipeline is projected to uplift the global P2X7 receptor antagonist market growth
Key manufacturer such as GlaxoSmithKline Plc, Johnson and Johnson, AstraZeneca plc, Asahi Kasei Corporation, and others have potential molecules in the pipeline.
Asahi Kasei Corporation, AstraZeneca Plc, and RaQualia Pharma Inc. have their products in preclinical stages for various indications such as analgesics, inflammation, and other indications.
GlaxoSmithKline Plc, Johnson & Johnson, and Evotec AG have these molecule for indications such as pain conditions, inflammatory conditions, major depressive disorder, and mood disorders.
Although, these molecules are in early stages of development, and faster clinical trials and active interest by companies such as Evotec AG, and Asahi Kasei Pharma to advance the pipeline is projected to support growth of the global P2X7 receptor antagonists market.
However, leading international manufacturers such as GlaxoSmithKline Plc. and AstraZeneca Plc. have not been actively pursuing the advancement of P2X7 receptor antagonist category. For instance, GlaxoSmithKline Plc’s P2X7 candidate GSK1482160 is still in Phase 1 clinical trials and the study ended in April 2009. Moreover, the category has less number of candidates in the pipeline as compared to other conditions such as cancer and others. This factor has affected global P2X7 receptor antagonist market growth.
Some of the key players operating in the global P2X7 receptor antagonist market include, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, RaQualia Pharma, Evotec AG, and Asahi Kasei Corporation.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/2595
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 P2X7 Receptor Antagonists Market Market Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: P2X7 Receptor Antagonists Market Market Industry Impact
Chapter 2 P2X7 Receptor Antagonists Market Market Competition by Types, Applications, and Top Regions and Countries
2.1 P2X7 Receptor Antagonists Market Market (Volume and Value) by Type
2.3 P2X7 Receptor Antagonists Market Market (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 P2X7 Receptor Antagonists Market Market Sales, Consumption, Export, Import by Regions
Chapter 5 North America P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 6 East Asia P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 7 Europe P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 8 South Asia P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 9 Southeast Asia P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 10 Middle East P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 11 Africa P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 12 Oceania P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 13 South America P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 14 Company Profiles and Key Figures in P2X7 Receptor Antagonists Market Market Business
Chapter 15 P2X7 Receptor Antagonists Market Market Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027